Objective : We assessed body composition, bone mineral density (BMD), glucose and lipids in Williams syndrome (WS), a rare microdeletion disorder. 
| INTRODUC TI ON
Williams syndrome (WS) is a microdeletion disorder involving loss of a contiguous stretch of 26-28 genes on chromosome 7q11.23. It is characterized by vascular stenoses, a distinctive pattern of neurodevelopmental findings, and several endocrine and metabolic abnormalities, including impaired glucose tolerance (IGT) and abnormal body composition. Previous work has shown that up to 75% of adults with WS have IGT or diabetes on oral glucose tolerance testing (OGTT) and also that bone mineral density (BMD) is decreased in WS. 1, 2 Moreover, clinical observations and preliminary data suggest increased overall body fat in adults with WS, as well as a relative increase in fat deposition in the lower extremities.
2 Genes in the deleted region include candidate genes that might underlie these abnormalities, such as syntaxin 1A (STX-1A) and carbohydrate-responsive element-binding protein (ChREBP), both of which are known to affect glucose and lipid metabolism, 3, 4 and LIM kinase 1 (LIMK1) and frizzled-9 (FZD9), both of which affect bone mass in animal models.
5
Although there is evidence that adults with WS have metabolic perturbations and abnormal body composition, these parameters remain incompletely characterized. The purpose of this study was to more comprehensively investigate body composition, bone density, metabolic parameters and interrelationships between these variables, in adults with WS. We demonstrate that individuals with WS, on average, have reduced lean mass, increased fat mass, decreased BMD and impaired glucose homeostasis. These findings have significant implications for clinical recommendations in this population. to have diabetes prior to study entry did not undergo OGTT.
| ME THODS
Venous access for phlebotomy could not be achieved for one subject with known diabetes, and sufficient venous access for an OGTT could not be obtained for one subject without known diabetes. Expected basal metabolic rate was calculated using the Harris-Benedict equation. 6 Indirect calorimetry data for one subject were discarded due to an implausible respiratory quotient of 1. 
| NHANES controls

| RE SULTS
This study included 22 individuals with WS, nine males and 13 females, with age range 16.5-48.3 years. Data from 88 age-, sex-and race-matched individuals from NHANES were used as a control group. Per design, there were no between-group differences in age (28.5 ± 7.9 years in WS, 28.5 ± 7.8 years in controls), sex (59.1% female in both groups) or race (90.9% white and 9.1% "other race"
in both groups). The WS subjects were substantially shorter than the NHANES controls (155.0 ± 6.5 vs 169.6 ± 9.2 cm, WS vs controls, P < 0.0001), whereas body weight was similar (72.0 ± 22.5 vs 71.7 ± 15.9 kg, WS vs controls, P = 0.92). Thus, the NHANES controls had substantially lower body mass index (BMI, 24.7 ± 4.3 kg/m 2 for controls vs 30.0 ± 9.3 kg/m 2 for WS, P = 0.0002).
| Body composition
Compared to controls, individuals with WS had more fat mass and less lean mass ( In analysis by sex, there remained marked reductions in lean mass in both males and females with WS compared to controls; this difference appeared especially pronounced for males (Supporting Information   Table S1 ). Per cent fat was higher in both males and females with WS, and tended to remain higher following adjustment for BMI, but adjusted subgroup analyses did not reach statistical significance.
After adjustment for BMI, body fat distribution, as assessed by android:gynoid ratio and trunk:limb fat ratio, was similar among WS subjects and controls. Four of the WS subjects, two males and two females, were clinically judged to have disproportionate lower extremity fat accumulation on examination with a lipedema-like phenotype. Anthropometric, metabolic and hormonal parameters for these patients are shown in Table 2 . Of these patients, two had severe lower extremity fat accumulation with cuffing at the ankles.
DXA scan and photograph of one of these patients are shown in Figure 2 .
TA B L E 1 Body composition, glucose and lipids, and bone density in WS and controls Table 1) . Modelling of 2-hour glucose by body composition showed that lean mass was inversely associated with 2-hour glucose levels (−1.3 mg/dL for each 1 kg increase in lean mass), whereas fat mass was positively associated (+1.4 mg/dL for each 1 kg increase in fat mass).
| Glucose and lipid metabolism
The presence of WS was not an effect modifier of these relationships.
Total cholesterol, triglycerides (TGL) and low-density lipoprotein (LDL) were all significantly lower in WS vs controls (Table 1) , whereas there was no difference in HDL-cholesterol. Four individuals with WS were taking statins. Excluding these individuals and their matched controls from the analysis, the difference in triglyceride between groups persisted, whereas the differences in total cholesterol and LDL were no longer statistically significant. Of note, even after excluding statin users with WS and their matched controls, the expected relationship between increased body fat and increased LDL and triglyceride that is seen in the general population was not seen in WS ( Figure 3A ,B). The presence of WS significantly modified the effect of body fat on both LDL (P = 0.03 for interaction of WS × body fat, Figure 3A ) and triglyceride (P = 0.04 for interaction term, Figure 3B ).
| Bone density, calcium and vitamin D
Total body BMD and total body less head (subtotal) BMD were significantly lower in individuals with WS compared to controls (Table 1) .
This difference persisted after adjusting for BMI, as shown in Table 1 , and was present in both males and females (Supporting Information Bone markers and sex steroid concentrations were measured in the individuals with WS (Table 3) . Reference values for NHANES controls were not available. In the WS cohort, estrone (r = 0.52, P = 0.02) was significantly positively associated with total BMD, with a similar association for subtotal BMD. In subgroup analyses by sex, the correlation coefficient for estrone and total BMD was similar in women (r = 0.63) and men (r = 0.62), but the association in men only trended towards significance (P = 0.07), whereas it remained significant in subgroup analysis for women (P = 0.03). PTH and bone turnover markers were not significantly associated with total or subtotal BMD (data not shown).
Parathyroid hormone (PTH), bone-specific alkaline phosphatase (BSAP) and plasma n-terminal telopeptide (NTX) were within the assay-specific normal ranges for all WS participants. Six individuals (3M, 3F) had elevated CTX, and five participants (2M, 3F) had elevated PINP, but these abnormalities did not correlate with lower total body BMD scores.
| Hormonal parameters
Thyroid-stimulating hormone (TSH) and free thyroxine (free T4)
were normal for all individuals with WS, but four of the 22 individuals studied were receiving levothyroxine for hypothyroidism.
With regard to gonadal steroids, one male with severe lipedemalike phenotype was frankly hypogonadal and also had elevated estrone F I G U R E 1 Relationship between body mass index and total body fat mass (A) and lean mass (B) in WS (O) and control (+) subjects. The association between increasing BMI and increasing fat mass is not different between WS and controls, but there is a significant difference in the association between increasing BMI and increasing lean mass (P-value = 0.008 for interaction between BMI and Williams syndrome status) and oestradiol (see Table 2 , patient 4). Another male had a borderline testosterone level (between 270 and 300 ng/mL) and elevated estrone, but normal oestradiol (see Table 2 , patient 2). Testosterone was normal in the other seven men studied, but estrone was above the assay reference range for two additional men with WS, for a total of four of nine men studied presenting with elevated estrone levels.
Five of the females studied were receiving some form of gonadal steroid treatment (either orally or through an intrauterine device). Of the remaining seven, SHBG, oestradiol and estrone levels were normal, but five had modest elevations in total testosterone (>70 ng/mL).
| Resting energy expenditure
Indirect calorimetry in individuals with WS showed that all individuals had a resting energy expenditure (REE) below that predicted by sex, weight, height and age, with mean per cent predicted REE of 84.6 ± 9.5%.
| D ISCUSS I ON
Our data indicate lower lean mass in WS individuals in spite of higher BMI, as well as an increased body fat percentage in WS compared to controls. Haemoglobin A1c and 2-hour blood glucose levels from an OGTT were elevated in patients with WS. After accounting for body composition differences, individuals with WS had lower triglyceride than controls. Finally, we show reduced BMD in both male and female individuals with WS, a difference that persists when adjusting for shorter stature in this group. Our sample size was not large enough to draw conclusions about associations between bone markers, hormone levels and the metabolic or bone phenotype of WS; however, our data show abnormal bone formation and bone turnover markers in some patients and also suggest that men with WS may benefit from testing for hypogonadism, whereas women with WS may have relatively high levels of total testosterone. 
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Total adiponectin (μg/mL) 9. Assay-specific normal ranges for hormonal parameters are as follows: oestradiol, 10-50 pg/mL in males, 30-400 pg/mL in premenopausal females; estrone, 10-60 pg/mL in males, 17-200 pg/mL in premenopausal females; total testosterone, 270-1070 ng/mL in males, 15- Table 2 ). In the DXA scan, yellow colouring denotes fat mass, red denotes muscle and blue denotes bone [Colour figure can be viewed at wileyonlinelibrary.com] F I G U R E 3 Relationship between total body fat and LDL cholesterol (A) and fasting triglyceride (B) in WS (O) and control (+) subjects.
There is a significant interaction between total body fat and Williams syndrome status (for interaction term, P = 0.03 for LDL, P = 0.04 for triglyceride), such that the expected increase in LDL and triglyceride with increasing body fat is not seen in Williams syndrome at least in part, due to the reduced lean mass in WS, the absence of indirect calorimetry data in controls leaves us unable to assess that hypothesis. Our findings contrast with those of Kaplan et al, 17 who reported a higher REE and per cent predicted REE, as well as lower body fat, in three adults with WS compared to three gendermatched adult controls. Given the small sample size of the Kaplan et al cohort and the lack of matched control data in our cohort, REE should be further studied in adults with WS.
Our findings that whole-body BMD is lower in both males and females with WS compared to controls are consistent with previous data from several studies. 2, 9, 18 To better understand factors that may contribute to this discrepancy, we examined 
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PTH was normal in all the WS individuals studied. CTX and P1NP were abnormal in a few subjects, and study of larger cohorts is needed to investigate whether these abnormalities are clinically relevant and whether they may be related to underlying genetics.
Genes in the WS critical region that potentially contribute to low bone mass include LIMK1 and FZD9. LIMK1 is a serine/threonine kinase that plays a role in cytoskeletal remodelling. 5 It is expressed in both osteoblasts and osteoclasts, and two studies have suggested an important role in osteoblast differentiation. 5, 21 LIMK1 null mice demonstrate a 5% reduction in total body BMD compared to controls. 5 Osteoblasts in LIMK1 null mice show reduced number and function, whereas osteoclasts are normal in number and demonstrate increased resorptive activity compared to LIMK +/− osteoclasts. 5 Serum CTX also tended to be higher in the knock-out animals compared to controls. 5 FZD9 is a Wnt receptor that promotes bone and further contribute to the evolving understanding of the hormonal, metabolic and body composition phenotype in WS. Our study, however, also has several limitations. Our results may be limited by sample size and the relatively young age of participants in our cohort and, therefore, not be applicable to older adults with WS. All data on subjects with WS were collected at MGH, whereas control data were extracted from the NHANES data set, with more limited availability and some differences in laboratory methodologies. Accordingly, comparison between WS and controls may have inherent bias that is difficult to characterize or quantify.
Additionally, due to lack of hormonal parameters in NHANES, we were unable to assess whether gonadal hormones and bone turnover markers differed in WS compared to controls. We have data on whole body and subtotal (whole body less head) BMD, but do not have data for site-specific BMD measurements such as the hip, forearm or lumbar spine. While both WS and NHANES DXA scans were performed on Hologic bone densitometers, they were done on different models (Discovery A vs QDR-4500A, respectively), potentially leading to minor systematic differences between results. Although the magnitude of differences we show between WS and controls is unlikely to be entirely attributable to differences between models, it will be important to validate these findings using WS and control individuals scanned on the same machine, and potentially using newer techniques such as high- 
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